EMA Panel Approves Bavarian Nordic's Vimkunya for Chikungunya Prevention

Bavarian Nordic A/S, a worldwide vaccine firm dedicated to enhancing health and saving lives via innovative vaccines, revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion supporting marketing authorization for Vimkunya (CHIKV VLP vaccine) for active immunization aimed at preventing chikungunya virus-related disease in individuals aged 12 and older.

Following an expedited evaluation, the CHMP’s recommendation mainly relies on findings from two phase 3 clinical studies that included over 3,500 healthy participants aged 12 and above, showing a swift immune response beginning to manifest within a week.

“The recommendation of our chikungunya vaccine for approval in Europe marks a huge milestone in our efforts to deliver protection against this debilitating disease and, once approved, would represent a significant contribution to expanding the availability of vaccines to a broader population, including adolescents aged 12-17 years,” said Paul Chaplin, president and CEO of Bavarian Nordic. “Chikungunya, like other mosquito-borne illnesses, represents an increasing public health risk across the globe due to factors such as climate change, and we look forward to making the vaccine available for travellers at risk later this year, while also continuing our efforts to expand access to endemic populations across the globe.”